Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

229 Clinical Updates found
Mark Souweidane continues advancing treatment for children with DIPG
Convection enhanced delivery, an innovative technique that directly infuses a therapeutic agent into a brain tumor through a cannula, bypassing the blood-brain barrier, is safe and feasible for treating diffuse intrinsic pontine glioma in children.
Lymphoma specialist Dr Anita Kumar with patient
Two important clinical trials to increase treatment options for mantle cell lymphoma patients are currently recruiting patients.
Microscopic image of adenocarcinoma lung cancer cells
In patients with resected pancreatic ductal adenocarcinoma, alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency genes were associated with favorable prognoses.
Our study, published recently in the Annals of Oncology, suggests that the greatest determinants of COVID-19 severity were patient features and comorbidities, such as a history of heavy smoking and chronic obstructive pulmonary disease (COPD).
T cell attacking cancer cells
In our paper, published recently in the journal Expert Review of Hematology, we review the main challenges with current CD19-targeted CAR, obstacles to adopting CAR T cell therapy in solid tumors, and various strategies scientists are pursuing to overcome these issues.
https://www.mskcc.org/clinical-updates/car-update-part-1-learning-and-opportunities-hematologic
This CAR T Update Part 2 summarizes the unique challenges with using CARS to defeat solid tumors, and how learning from preclinical and clinical research in hematologic malignancies is informing new strategies and research efforts.
Bill Tap, Chief of MSK's Sarcoma Medical Oncology Service
The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.
Surgery at MSK
Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.
CAR T cells attacking cancer
Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite Covid-19 according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S. academic institutions.
Breast radiation therapy
During the early days of the COVID-19 outbreak, a team of radiation oncologists specializing in breast cancer management at Memorial Sloan Kettering Cancer Center reviewed the literature and established recommendations for the safe use of hypofractionated and abbreviated radiation regimens for our patients with breast cancer.